Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin Dilger

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Inflammatory Bowel Diseases|March 24, 2010
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitisTilo Andus, Andreas Kocjan, Moritz Müser, et al.
Journal of Crohn'S & Colitis|October 7, 2016
A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's DiseaseJürgen Schölmerich, Klaus Fellermann, Frank W Seibold, et al.
Gut|March 21, 2015
A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitisStephan Miehlke, Petr Hruz, Michael Vieth, et al.
Gastroenterology|November 13, 2010
Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's diseaseAndreas Tromm, Ivan Bunganič, Eva Tomsová, et al.
Gut|November 27, 2014
Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trialAndreas Münch, Johan Bohr, Stephan Miehlke, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Inflammatory Bowel Diseases|March 24, 2010
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitisTilo Andus, Andreas Kocjan, Moritz Müser, et al.
Journal of Crohn'S & Colitis|October 7, 2016
A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's DiseaseJürgen Schölmerich, Klaus Fellermann, Frank W Seibold, et al.
Gut|March 21, 2015
A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitisStephan Miehlke, Petr Hruz, Michael Vieth, et al.
Gastroenterology|November 13, 2010
Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's diseaseAndreas Tromm, Ivan Bunganič, Eva Tomsová, et al.
Gut|November 27, 2014
Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trialAndreas Münch, Johan Bohr, Stephan Miehlke, et al.
Pageof 3